ERBB2 and breast cancer: We utilized breast cancer samples from The Cancer Genome Atlas (TCGA; n = 755) [21], which were subclassified using the PAM50 algorithm into HER2+, basal, luminal A and luminal B subtypes [22], and assessed the fold enrichment of APOBEC3 signature mutations in each sample.